The rationale of anticoagulants in the treatment of cancer.
D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D002430:Cecal Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005341:Fibrinolysin / Q000494:pharmacology / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D008223:Lymphoma / Q000188:drug therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D009360:Neoplastic Cells, Circulating; D010051:Ovarian Neoplasms / Q000532:radiotherapy; D010386:Pelvic Neoplasms / Q000532:radiotherapy; D011817:Rabbits; D013274:Stomach Neoplasms / Q000188:drug therapy; D013552:Swine; D013927:Thrombosis / Q000188:drug therapy / Q000209:etiology; D014683:Vena Cava, Superior; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014859:Warfarin; D006493:Heparin; D005341:Fibrinolysin